Alvita Pharma Private Limited

Alvita Pharma Private Limited, established on January 23, 2010, is a privately held pharmaceutical company headquartered in Mumbai, India. The company is registered under the Corporate Identification Number (CIN) U24230GJ2010PTC059305, with its registered office located at B-203, Gopal Palace, Near Nehru Nagar Circle, Satellite Road, Ambavadi, Ahmedabad, Gujarat, 380015.

The authorized capital of Alvita Pharma is ₹100 million, with a paid-up capital of ₹90 million. As of the latest available data, the company employs between 11 to 50 individuals. Alvita Pharma specializes in the manufacturing of pharmaceutical products, including tablets, capsules, syrups, and injections, across various therapeutic categories.

Alvita Pharma operates manufacturing facilities in Mumbai and Vadodara, Gujarat. The Vadodara unit is fully operational and was expected to obtain European Union approval by March 2023. These facilities are equipped to produce a wide range of finished pharmaceutical formulations, ensuring compliance with international quality standards.

The leadership team at Alvita Pharma includes:

• Surendra Kumar Lohia: Director
• Manoj Ramaniklal Vora: Director
• Sajan Parmeswaran Unnithan: Director

These individuals play pivotal roles in steering the company's strategic direction and operations.

Alvita Pharma has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing unit in Vadodara was anticipated to receive European Union approval by March 2023, indicating its commitment to meeting stringent international regulatory standards. While specific details regarding regulatory filings and approvals in other markets are not publicly disclosed, Alvita Pharma's adherence to EU GMP standards suggests a proactive approach to obtaining necessary certifications for these regions.

Alvita Pharma has expanded its footprint into emerging markets across Africa, Southeast Asia, and Eastern Europe. The company markets over 600 products in therapeutic segments such as anti-malarial, gastrointestinal, antibiotics, cardiology, dermatology, and pain management. This diverse portfolio enables Alvita Pharma to address the healthcare needs of various populations, leveraging WHO prequalification to enhance access to quality medicines in these regions.

Alvita Pharma's geographic strategy focuses on diversification across multiple continents, including Africa, Southeast Asia, and Eastern Europe. By marketing over 600 products in various therapeutic segments, the company mitigates concentration risk and positions itself to capitalize on growth opportunities in diverse markets. This approach reflects a strategic direction aimed at building a robust global presence.

Specific details regarding Alvita Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's commitment to obtaining European Union approval for its Vadodara manufacturing unit by March 2023 suggests a proactive approach to meeting international regulatory standards, which may include FDA requirements.

Alvita Pharma's Vadodara manufacturing unit was expected to obtain European Union approval by March 2023, indicating compliance with EU Good Manufacturing Practice (GMP) standards. While specific details regarding WHO prequalification are not publicly disclosed, the company's adherence to EU GMP standards suggests a commitment to meeting international quality benchmarks.

Alvita Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained approvals from state drug controllers. The company has also secured export No Objection Certificates (NOCs), facilitating its international trade operations. These regulatory compliances underscore Alvita Pharma's commitment to maintaining high-quality manufacturing standards and adhering to Indian regulatory requirements.

As of March 28, 2026, there are no publicly available records indicating that Alvita Pharma has received Form 483 observations, warning letters, or import alerts from regulatory authorities. The company's proactive approach to obtaining European Union approval for its Vadodara manufacturing unit by March 2023 suggests a commitment to maintaining compliance with international regulatory standards.

Alvita Pharma operates in a competitive landscape alongside major pharmaceutical companies such as Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Zydus Lifesciences Ltd., and Lupin Ltd. While Alvita Pharma's market share in overlapping categories is not publicly disclosed, its focus on branded generics and diverse therapeutic segments positions it to compete effectively in both domestic and international markets.

Alvita Pharma's key differentiators include its extensive product portfolio of over 600 products across various therapeutic segments, advanced research facilities in Mumbai and Vadodara, and a commitment to launching first-to-market products in different countries. These strengths enable the company to provide high-quality and affordable medicines to a diverse patient base.

Alvita Pharma's current strategic direction focuses on expanding its branded generic business across Africa, Southeast Asia, and Eastern Europe. The company is actively involved in business development and licensing to launch innovative molecules and formulations in the Indian market. Looking ahead, Alvita Pharma aims to strengthen its global presence by leveraging its manufacturing capabilities and diverse product portfolio to meet the evolving healthcare needs of various regions.

Alvita Pharma has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $479,000 USD across 17 shipments. The company's portfolio concentration, with its top five products accounting for 100% of exports, indicates a focused approach to its product offerings. The proactive steps taken to obtain European Union approval for its Vadodara manufacturing unit by March 2023 further underscore its commitment to quality and compliance.

Importers should verify the following certifications when considering Alvita Pharma as a supplier:

• FDA Registration: Confirm the company's FDA facility registration status through the FDA's official website.
• WHO-GMP Certification: Check the World Health Organization's official website for prequalification status.
• EU GMP Certification: Verify the European Medicines Agency's website for GMP compliance status.
• ISO Certification: Request copies of ISO certificates from Alvita Pharma and verify their authenticity through the International Organization for Standardization's website.

When conducting due diligence on Alvita Pharma, consider the following steps:

• Verify Regulatory Compliance: Confirm the company's compliance with relevant regulatory bodies, including the FDA, WHO, EU, and CDSCO.
• Assess Financial Health: Review the company's financial statements and credit history to evaluate financial stability.
• Evaluate Manufacturing Capabilities: Inspect manufacturing facilities for adherence to quality standards and capacity to meet demand.
• Check References: Contact current and past clients to assess reliability and product quality.
• Monitor for Red Flags: Be alert to any signs of regulatory non-compliance, financial instability, or quality issues.

By following this checklist, importers can make informed decisions regarding potential partnerships with Alvita Pharma.